|
Originally published In Press as doi:10.1074/jbc.M403096200 on June 16, 2004
J. Biol. Chem., Vol. 279, Issue 35, 36372-36381, August 27, 2004
Molecular Basis of the Differential Sensitivity of Nematode and Mammalian Muscle to the Anthelmintic Agent Levamisole*
Diego Rayes,
María José De Rosa,
Mariana Bartos, and
Cecilia Bouzat
From the
Instituto de Investigaciones Bioquímicas de Bahía Blanca, UNS-CONICET, B-8000FWB Bahía Blanca, Argentina
Levamisole is an anthelmintic agent that exerts its therapeutic effect by acting as a full agonist of the nicotinic receptor (AChR) of nematode muscle. Its action at the mammalian muscle AChR has not been elucidated to date despite its wide use as an anthelmintic in humans and cattle. By single channel and macroscopic current recordings, we investigated the interaction of levamisole with the mammalian muscle AChR. Levamisole activates mammalian AChRs. However, single channel openings are briefer than those activated by acetylcholine (ACh) and do not appear in clusters at high concentrations. The peak current induced by levamisole is about 3% that activated by ACh. Thus, the anthelmintic acts as a weak agonist of the mammalian AChR. Levamisole also produces open channel blockade of the AChR. The apparent affinity for block (190 µM at 70 mV) is similar to that of the nematode AChR, suggesting that differences in channel activation kinetics govern the different sensitivity of nematode and mammalian muscle to anthelmintics. To identify the structural basis of this different sensitivity, we performed mutagenesis targeting residues in the subunit that differ between vertebrates and nematodes. The replacement of the conserved Gly-153 with the homologous glutamic acid of nematode AChR significantly increases the efficacy of levamisole to activate channels. Channel activity takes place in clusters having two different kinetic modes. The kinetics of the high open probability mode are almost identical when the agonist is ACh or levamisole. It is concluded that Gly-153 is involved in the low efficacy of levamisole to activate mammalian muscle AChRs.
Received for publication, March 19, 2004
, and in revised form, May 28, 2004.
* This work was supported by grants from Universidad Nacional del Sur, Agencia Nacional de Promoción Científica y Tecnológica, International Society for Neurochemistry, CONICET (to C. B.), and FIRCA Grant 1R03 TW01185-01 (to C. B. and Steven Sine, Principal Investigator of the FIRCA Grant, Mayo Clinic and Foundation, Rochester, MN). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom correspondence should be addressed: Instituto de Investigaciones Bioquímicas de Bahía Blanca, UNS-CONICET, CC857, Camino La Carrindanga Km 7-B8000FWB Bahía Blanca, Argentina. Fax: 54-291-4861200; E-mail: inbouzat{at}criba.edu.ar.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
T. Boulin, M. Gielen, J. E. Richmond, D. C. Williams, P. Paoletti, and J.-L. Bessereau
Eight genes are required for functional reconstitution of the Caenorhabditis elegans levamisole-sensitive acetylcholine receptor
PNAS,
November 25, 2008;
105(47):
18590 - 18595.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T.-Y. Wu, C. M. Smith, S. M. Sine, and M. M. Levandoski
Morantel Allosterically Enhances Channel Gating of Neuronal Nicotinic Acetylcholine {alpha}3{beta}2 Receptors
Mol. Pharmacol.,
August 1, 2008;
74(2):
466 - 475.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Bartos, D. Rayes, and C. Bouzat
Molecular Determinants of Pyrantel Selectivity in Nicotinic Receptors
Mol. Pharmacol.,
October 1, 2006;
70(4):
1307 - 1318.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2004 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|